FDA warns telehealth firms over compounded GLP-1 weight-loss drug claims

The agency sent 25 warning letters last month as doctors caution that cheaper compounded versions lack proof of safety, effectiveness and consistent manufacturing.

Summary

verifying reliability

Terms & Concepts

No specialized terms available for this topic.